50 semaglutide Oral mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial 50 lbs down and a

Detection of viruses in myocardial tissues by polymerase chain reaction: evidence of adenovirus as a common cause of myocarditis in children and adults

Erythrocyte membrane characteristics indicate abnormal cellular aging in patients with Alzheimers disease

Orforglipron and retatrutide from Eli Lilly exemplify the next generation of metabolic therapies: oral formulations that promise improved adherence, triple-hormone mechanisms that deliver superior weight loss and expanded therapeutic applications spanning from brain health to renal disease". For 2026, pharma executives must recognize that metabolic innovation extends far beyond replicating existing GLP-1 therapies, the report authors wrote

This pricing covers the medication itself